The effect of thymosin α1 for prevention of infection in patients with severe acute pancreatitis

References

• Tenner S, Baillie J, DeWitt J, et al. American college of gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(1400–15):1416.
   Google Scholar
• Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62:102–111.
   PubMed Web of Science ®Google Scholar
• Forsmark CE, Vege SS, Wilcox CM. Acute pancreatitis. N Engl J Med. 2016;375:1972–1981.
   PubMed Web of Science ®Google Scholar
• van Dijk SM, Hallensleben NDL, van Santvoort HC, et al. Acute pancreatitis: recent advances through randomised trials. Gut. 2017;66:2024–2032.
   PubMed Web of Science ®Google Scholar
• Xue P, Deng LH, Zhang ZD, et al. Infectious complications in patients with severe acute pancreatitis. Dig Dis Sci. 2009;54:2748–2753.
   PubMed Web of Science ®Google Scholar
• Brown LA, Hore TA, Phillips AR, et al. A systematic review of the extra-pancreatic infectious complications in acute pancreatitis. Pancreatology. 2014;14:436–443.
   PubMed Web of Science ®Google Scholar
• Petrov MS, Shanbhag S, Chakraborty M, et al. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010;139:813–820.
   PubMed Web of Science ®Google Scholar
• Li J, Yang WJ, Huang LM, et al. Immunomodulatory therapies for acute pancreatitis. World J Gastroenterol. 2014;20:16935–16947.
   PubMed Web of Science ®Google Scholar
• Lin ZQ, Guo J, Xia Q, et al. Human leukocyte antigen-DR expression on peripheral monocytes may be an early marker for secondary infection in severe acute pancreatitis. Hepatogastroenterology. 2013;60:1896–1902.
   PubMedGoogle Scholar
• Shen X, Sun J, Ke L, et al. Reduced lymphocyte count as an early marker for predicting infected pancreatic necrosis. BMC Gastroenterol. 2015;15:147.
   PubMed Web of Science ®Google Scholar
• Yu WK, Li WQ, Li N, et al. Mononuclear histocompatibility leukocyte antigen-DR expression in the early phase of acute pancreatitis. Pancreatology. 2004;4:233–243.
   PubMed Web of Science ®Google Scholar
• Shen Y, Deng X, Xu N, et al. Relationship between the degree of severe acute pancreatitis and patient immunity. Surg Today. 2015;45:1009–1017.
   PubMed Web of Science ®Google Scholar
• Pinhu L, Qin Y, Xiong B, et al. Overexpression of Fas and FasL is associated with infectious complications and severity of experimental severe acute pancreatitis by promoting apoptosis of lymphocytes. Inflammation. 2014;37:1202–1212.
   PubMed Web of Science ®Google Scholar
• Qin Y, Pinhu L, You Y, et al. The role of Fas expression on the occurrence of immunosuppression in severe acute pancreatitis. Dig Dis Sci. 2013;58:3300–3307.
   PubMed Web of Science ®Google Scholar
• Pan T, Zhou T, Li L, et al. Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis. Crit Care. 2017;21:186.
   PubMed Web of Science ®Google Scholar
• Chen Y, Li M, Liu J, et al. sPD-L1 expression is associated with immunosuppression and infectious complications in patients with acute pancreatitis. Scand J Immunol. 2017;86:100–106.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Lou J, et al. Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care. 2011;15:R70.
   PubMed Web of Science ®Google Scholar
• Dionigi R, Rovera F, Dionigi G, et al. Infected pancreatic necrosis. Surg Infect (Larchmt). 2006;7(Suppl 2):S49–52.
   PubMedGoogle Scholar
• Kazantsev GB, Hecht DW, Rao R, et al. Plasmid labeling confirms bacterial translocation in pancreatitis. Am J Surg. 1994;167:201–206; discussion 206-7.
   PubMed Web of Science ®Google Scholar
• Fritz S, Hackert T, Hartwig W, et al. Bacterial translocation and infected pancreatic necrosis in acute necrotizing pancreatitis derives from small bowel rather than from colon. Am J Surg. 2010;200:111–117.
   PubMed Web of Science ®Google Scholar
• Koh YY, Jeon WK, Cho YK, et al. The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. Gut Liver. 2012;6:505–511.
   PubMed Web of Science ®Google Scholar
• Sharma M, Sachdev V, Singh N, et al. Alterations in intestinal permeability and endotoxemia in severe acute pancreatitis. Trop Gastroenterol. 2012;33:45–50.
   PubMedGoogle Scholar
• Ammori BJ, Leeder PC, King RF, et al. Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg. 1999;3:252–262.
   PubMed Web of Science ®Google Scholar
• Qiao SF, Lu TJ, Sun JB, et al. Alterations of intestinal immune function and regulatory effects of L-arginine in experimental severe acute pancreatitis rats. World J Gastroenterol. 2005;11:6216–6218.
   PubMed Web of Science ®Google Scholar
• Jiang K, Huang W, Yang XN, et al. Present and future of prophylactic antibiotics for severe acute pancreatitis. World J Gastroenterol. 2012;18:279–284.
   PubMed Web of Science ®Google Scholar
• Sainio V, Kemppainen E, Puolakkainen P, et al. Early antibiotic treatment in acute necrotising pancreatitis. Lancet. 1995;346:663–667.
   PubMed Web of Science ®Google Scholar
• Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a randomized, double-blind, placebo-controlled study. Ann Surg. 2007;245:674–683.
   PubMed Web of Science ®Google Scholar
• Jafri NS, Mahid SS, Idstein SR, et al. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis. Am J Surg. 2009;197:806–813.
   PubMed Web of Science ®Google Scholar
• Ukai T, Shikata S, Inoue M, et al. Early prophylactic antibiotics administration for acute necrotizing pancreatitis: a meta-analysis of randomized controlled trials. J Hepatobiliary Pancreat Sci. 2015;22:316–321.
   PubMed Web of Science ®Google Scholar
• Petrov MS, Kukosh MV, Emelyanov NV. A randomized controlled trial of enteral versus parenteral feeding in patients with predicted severe acute pancreatitis shows a significant reduction in mortality and in infected pancreatic complications with total enteral nutrition. Dig Surg. 2006;23:336–344; discussion 344-5.
   PubMed Web of Science ®Google Scholar
• Yi F, Ge L, Zhao J, et al. Meta-analysis: total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. Intern Med. 2012;51:523–530.
   PubMed Web of Science ®Google Scholar
• Li JY, Yu T, Chen GC, et al. Enteral nutrition within 48 hours of admission improves clinical outcomes of acute pancreatitis by reducing complications: a meta-analysis. PLoS One. 2013;8:e64926.
   PubMed Web of Science ®Google Scholar
• Reintam Blaser A, Starkopf J, Alhazzani W, et al. Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines. Intensive Care Med. 2017;43:380–398.
   PubMed Web of Science ®Google Scholar
• Knight DJ, Girling KJ. Gut flora in health and disease. Lancet. 2003;361:1831.
   PubMedGoogle Scholar
• Gu WJ, Liu JC. Probiotics in patients with severe acute pancreatitis. Crit Care. 2014;18:446.
   PubMed Web of Science ®Google Scholar
• Olah A, Belagyi T, Issekutz A, et al. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg. 2002;89:1103–1107.
   PubMed Web of Science ®Google Scholar
• Plaudis H, Pupelis G, Zeiza K, et al. Early low volume oral synbiotic/prebiotic supplemented enteral stimulation of the gut in patients with severe acute pancreatitis: a prospective feasibility study. Acta Chir Belg. 2012;112:131–138.
   PubMed Web of Science ®Google Scholar
• Venkatesan T. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Nutr Clin Pract. 2008;23:662–663.
   PubMed Web of Science ®Google Scholar
• Gou S, Yang Z, Liu T, et al. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2014;18:R57.
   PubMed Web of Science ®Google Scholar
• Oates KK, Erdos M. Biochemical identification of thymosin alpha-1: its phylogenetic distribution and evolutionary implications. Comp Biochem Physiol B. 1989;94:759–763.
   PubMed Web of Science ®Google Scholar
• Weller FE, Shah U, Cummings GD, et al. Serum levels of immunoreactive thymosin alpha 1 and thymosin beta 4 in large cohorts of healthy adults. Thymus. 1992;19:45–52.
   PubMedGoogle Scholar
• Camerini R, Garaci E. Historical review of thymosin alpha 1 in infectious diseases. Expert Opin Biol Ther. 2015;15(Suppl 1):S117–27.
   PubMedGoogle Scholar
• Serafino A, Pierimarchi P, Pica F, et al. Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response. Ann N Y Acad Sci. 2012;1270:13–20.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood. 2006;108:2265–2274.
   PubMed Web of Science ®Google Scholar
• Pierluigi B, D’Angelo C, Fallarino F, et al. Thymosin alpha1: the regulator of regulators? Ann N Y Acad Sci. 2010;1194:1–5.
   PubMed Web of Science ®Google Scholar
• Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody–and hepatitis B virus DNA–positive chronic hepatitis B. Hepatology. 1996;24:774–777.
   PubMed Web of Science ®Google Scholar
• King CWTRS. Thymosin apha 1–A peptide immune modulator with a broad range of clinical applications. Clin Exp Pharmacol. 2013;3:133.
   Google Scholar
• Li C, Bo L, Liu Q, et al. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis. 2015;33:90–96.
   PubMed Web of Science ®Google Scholar
• Ishitsuka H, Umeda Y, Nakamura J, et al. Protective activity of thymosin against opportunistic infections in animal models. Cancer Immunol Immunother. 1983;14:145–150.
   PubMed Web of Science ®Google Scholar
• Ershler WB, Hebert JC, Blow AJ, et al. Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged mice. Int J Immunopharmacol. 1985;7:465–471.
   PubMed Web of Science ®Google Scholar
• Cheng-Hong LI, Wang CH, Meng QH, et al. Effect of the thymosin alpha_1 on immune function in aged chronic obstructive pulmonary disease during acute period. Chin J Hosp Pharm. 2007;27:637–639.
   Google Scholar
• Ruggeri L, Perruccio K, Pierini A, et al. Thymosin alfa 1 administration improves immune reconstitution and decreases infection-related mortality after HLA-matched sibling T cell-depleted stem cell transplantation. 2011;118:1013.
   Google Scholar
• Yao W, Zhu Q, Yuan Y, et al. Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level. J Gastroenterol Hepatol. 2007;22:1866–1871.
   PubMed Web of Science ®Google Scholar
• Xue J, Sharma V, Habtezion A. Immune cells and immune-based therapy in pancreatitis. Immunol Res. 2014;58:378–386.
   PubMed Web of Science ®Google Scholar
• Wang X, Zeng X, Yang B, et al. Efficacy of thymosin alpha1 and interferon alpha for the treatment of severe acute pancreatitis in a rat model. Mol Med Rep. 2015;12:6775–6781.
   PubMed Web of Science ®Google Scholar
• Akinosoglou K, Gogos C. Immune-modulating therapy in acute pancreatitis: fact or fiction. World J Gastroenterol. 2014;20:15200–15215.
   PubMed Web of Science ®Google Scholar
• Shamoon M, Deng Y, Chen YQ, et al. Therapeutic implications of innate immune system in acute pancreatitis. Expert Opin Ther Targets. 2016;20:73–87.
   PubMed Web of Science ®Google Scholar
• Li WD, Jia L, Ou Y, et al. Infliximab: protective effect to intestinal barrier function of rat with acute necrosis pancreatitis at early stage. Pancreas. 2013;42:366–367.
   PubMed Web of Science ®Google Scholar
• Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995;82:1414–1420.
   PubMed Web of Science ®Google Scholar
• McKay CJ, Curran F, Sharples C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg. 1997;84:1239–1243.
   PubMed Web of Science ®Google Scholar
• Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut. 2001;48:62–69.
   PubMed Web of Science ®Google Scholar
• Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis. Evidence of improvement in disease severity. Dig Dis Sci. 1993;38:644–647.
   PubMed Web of Science ®Google Scholar
• Binder M, Uhl W, Friess H, et al. Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with three different octreotide dosages. Digestion. 1994;55(Suppl 1):20–23.
   PubMedGoogle Scholar
• Fiedler F, Jauernig G, Keim V, et al. Octreotide treatment in patients with necrotizing pancreatitis and pulmonary failure. Intensive Care Med. 1996;22:909–915.
   PubMed Web of Science ®Google Scholar
• McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol. 1997;21:13–19.
   PubMedGoogle Scholar
• Uhl W, Buchler MW, Malfertheiner P, et al. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut. 1999;45:97–104.
   PubMed Web of Science ®Google Scholar
• Karakoyunlar O, Sivrel E, Tanir N, et al. High dose octreotide in the management of acute pancreatitis. Hepatogastroenterology. 1999;46:1968–1972.
   PubMedGoogle Scholar
• Paran H, Mayo A, Paran D, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci. 2000;45:2247–2251.
   PubMed Web of Science ®Google Scholar
• Nikou GC, Arnaoutis TP, Giamarellos-Bourboulis EJ, et al. The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. Hepatogastroenterology. 2001;48:1754–1757.
   PubMedGoogle Scholar
• Nikou GC, Giamarellos-Bourboulis EJ, Grecka P, et al. Effect of octreotide administration on serum interleukin-6 (IL-6) levels of patients with acute edematous pancreatitis. Hepatogastroenterology. 2004;51:599–602.
   PubMedGoogle Scholar
• Yang F, Wu H, Li Y, et al. Prevention of severe acute pancreatitis with octreotide in obese patients: a prospective multi-center randomized controlled trial. Pancreas. 2012;41:1206–1212.
   PubMed Web of Science ®Google Scholar
• Wang R, Yang F, Wu H, et al. High-dose versus low-dose octreotide in the treatment of acute pancreatitis: a randomized controlled trial. Peptides. 2013;40:57–64.
   PubMed Web of Science ®Google Scholar
• Wang X, Li W, Niu C, et al. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study. Inflammation. 2011;34:198–202.
   PubMed Web of Science ®Google Scholar
• Sivasankar A, Kannan DG, Ravichandran P, et al. Outcome of severe acute pancreatitis: is there a role for conservative management of infected pancreatic necrosis? Hepatobiliary Pancreat Dis Int. 2006;5:599–604.
   PubMedGoogle Scholar
• Shen Y, Cui N, Miao B, et al. Immune dysregulation in patients with severe acute pancreatitis. Inflammation. 2011;34:36–42.
   PubMed Web of Science ®Google Scholar
• Romani L, Bistoni F, Montagnoli C, et al. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 2007;1112:326–338.
   PubMed Web of Science ®Google Scholar